U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H17NO2
Molecular Weight 267.323
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of APOMORPHINE

SMILES

CN1CCc2cccc-3c2[C@@]1([H])Cc4ccc(c(c43)O)O

InChI

InChIKey=VMWNQDUVQKEIOC-CYBMUJFWSA-N
InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1

HIDE SMILES / InChI
Molecular Formula C17H17NO2
Molecular Weight 267.323
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Apomorphine (brand names: Apokyn, Ixense, Spontane, Uprima) is indicated for the acute, intermittent treatment of hypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced Parkinson’s disease. Apomorphine has been studied as an adjunct to other medications. It is a non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, and D5, and adrenergic α1D, α2B, α2C receptors. The precise mechanism of action as a treatment for Parkinson’s disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D2-type receptors within the caudate-putamen in the brain.

CNS Activity

CNS Active
3730
Curator's Comment:: Apomorphine quickly passes the nasal and intestinal mucosa as well as the blood-brain barrier (depending on the administration route)

Approval Year

1880
9
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2470
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8043
APOKYN

Approved Use

APOKYN (apomorphine hydrochloride injection) is indicated for the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) in patients with advanced Parkinson's disease. APOKYN has been studied as an adjunct to other medications [see Clinical Studies (14)

Launch Date

1.08241918E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
47.5 pmol/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2774511/
30 μg/kg bw single, subcutaneous
dose: 30 μg/kg bw
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
APOMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
41.7 pmol × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2774511/
30 μg/kg bw single, subcutaneous
dose: 30 μg/kg bw
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
APOMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
33.6 min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2774511/
30 μg/kg bw single, subcutaneous
dose: 30 μg/kg bw
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
APOMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4 mg single, respiratory
Highest studied dose
Dose: 4 mg
Route: respiratory
Route: single
Dose: 4 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 5
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
1.5 mg single, respiratory
Recommended
Dose: 1.5 mg
Route: respiratory
Route: single
Dose: 1.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 32
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Other AEs: Somnolence, Dysgeusia...
Other AEs:
Somnolence (1 patient)
Dysgeusia (1 patient)
Dizziness (1 patient)
Orthostatic hypotension (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
2.3 mg single, respiratory
Recommended
Dose: 2.3 mg
Route: respiratory
Route: single
Dose: 2.3 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 18
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 18
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
3 mg single, respiratory
Recommended
Dose: 3 mg
Route: respiratory
Route: single
Dose: 3 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 12
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Other AEs: Somnolence, Yawning...
Other AEs:
Somnolence (1 patient)
Yawning (1 patient)
Flushing (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Disc. AE: Cognitive impairment, Skin reaction...
AEs leading to
discontinuation/dose reduction:
Cognitive impairment (16 patients)
Skin reaction (14 patients)
Posture abnormal (12 patients)
Psychosis (11 patient)
Anxiety/depression (11 patient)
Hypotension (3 patients)
Gastrointestinal disorder (NOS) (1 patient)
Cardiovascular disorder (1 patient)
Weight loss (1 patient)
Excessive daytime sleepiness (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
4 mg 1 times / day multiple, subcutaneous (mean)
Highest studied dose
Dose: 4 mg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18978491/
unhealthy, 65.21 years
n = 546
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 65.21 years
Sex: M+F
Population Size: 546
Sources:
https://pubmed.ncbi.nlm.nih.gov/18978491/
Disc. AE: Nausea and vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea and vomiting (187 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18978491/
10 mg 1 times / day steady, subcutaneous (max)
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Co-administed with::
trimethobenzamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 4
unhealthy, adult
n = 522
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: adult
Sex: unknown
Population Size: 522
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 4
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (3%)
Vomiting (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 4
10 mg 1 times / day steady, subcutaneous (max)
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 5
unhealthy, adult
n = 522
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: adult
Sex: unknown
Population Size: 522
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 5
Disc. AE: Hallucination...
AEs leading to
discontinuation/dose reduction:
Hallucination (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 5
35 mg 1 times / day steady, sublingual (max)
Recommended
Dose: 35 mg, 1 times / day
Route: sublingual
Route: steady
Dose: 35 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31818699/
unhealthy, mean 62.9 years
n = 54
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: mean 62.9 years
Sex: M+F
Population Size: 54
Sources:
https://pubmed.ncbi.nlm.nih.gov/31818699/
Disc. AE: Respiratory tract signs and symptoms...
AEs leading to
discontinuation/dose reduction:
Respiratory tract signs and symptoms (9 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/31818699/
AEs

AEs

AESignificanceDosePopulation
Dizziness 1 patient
1.5 mg single, respiratory
Recommended
Dose: 1.5 mg
Route: respiratory
Route: single
Dose: 1.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 32
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Dysgeusia 1 patient
1.5 mg single, respiratory
Recommended
Dose: 1.5 mg
Route: respiratory
Route: single
Dose: 1.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 32
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Orthostatic hypotension 1 patient
1.5 mg single, respiratory
Recommended
Dose: 1.5 mg
Route: respiratory
Route: single
Dose: 1.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 32
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Somnolence 1 patient
1.5 mg single, respiratory
Recommended
Dose: 1.5 mg
Route: respiratory
Route: single
Dose: 1.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 32
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Flushing 1 patient
3 mg single, respiratory
Recommended
Dose: 3 mg
Route: respiratory
Route: single
Dose: 3 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 12
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Somnolence 1 patient
3 mg single, respiratory
Recommended
Dose: 3 mg
Route: respiratory
Route: single
Dose: 3 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 12
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Yawning 1 patient
3 mg single, respiratory
Recommended
Dose: 3 mg
Route: respiratory
Route: single
Dose: 3 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
unhealthy, 30 - 90 years
n = 12
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 30 - 90 years
Sex: unknown
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/23527823/
Page: Table 2
Cardiovascular disorder 1 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Excessive daytime sleepiness 1 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Gastrointestinal disorder (NOS) 1 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Weight loss 1 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Anxiety/depression 11 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Psychosis 11 patient
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Posture abnormal 12 patients
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Skin reaction 14 patients
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Cognitive impairment 16 patients
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Hypotension 3 patients
Disc. AE
10 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
unhealthy, 44 - 87 years
n = 114
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 44 - 87 years
Sex: M+F
Population Size: 114
Sources:
https://pubmed.ncbi.nlm.nih.gov/31111272/
Page: Fig. 1
Nausea and vomiting 187 patients
Disc. AE
4 mg 1 times / day multiple, subcutaneous (mean)
Highest studied dose
Dose: 4 mg, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18978491/
unhealthy, 65.21 years
n = 546
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: 65.21 years
Sex: M+F
Population Size: 546
Sources:
https://pubmed.ncbi.nlm.nih.gov/18978491/
Vomiting 2%
Disc. AE
10 mg 1 times / day steady, subcutaneous (max)
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Co-administed with::
trimethobenzamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 4
unhealthy, adult
n = 522
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: adult
Sex: unknown
Population Size: 522
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 4
Nausea 3%
Disc. AE
10 mg 1 times / day steady, subcutaneous (max)
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Co-administed with::
trimethobenzamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 4
unhealthy, adult
n = 522
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: adult
Sex: unknown
Population Size: 522
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 4
Hallucination 1%
Disc. AE
10 mg 1 times / day steady, subcutaneous (max)
Recommended
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 5
unhealthy, adult
n = 522
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: adult
Sex: unknown
Population Size: 522
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf
Page: 5
Respiratory tract signs and symptoms 9 patients
Disc. AE
35 mg 1 times / day steady, sublingual (max)
Recommended
Dose: 35 mg, 1 times / day
Route: sublingual
Route: steady
Dose: 35 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31818699/
unhealthy, mean 62.9 years
n = 54
Health Status: unhealthy
Condition: Parkinson's disease
Age Group: mean 62.9 years
Sex: M+F
Population Size: 54
Sources:
https://pubmed.ncbi.nlm.nih.gov/31818699/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inducer
707
inhibitor
1604
inhibitor
1702

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1383

CYP2B6
717

CYP2C8
818

CYP2C19
1325

CYP3A4/5
241

BCRP
643

BSEP
376

P-gp
1330

MRP2
346

MRP3
150

MRP4
194

MATE1
290

MATE2
251

OATP1B1
733

OATP1B3
657

OAT1
554

OAT3
588

OCT1
480

OCT2
594
UGT
173

sulfotransferases
33

CYP2B6
616

CYP2C8
634

CYP3A4/5
76
CYP1A2
637

CYP2B6
501

OCT1
19

P-gp
248

MRP2
107

MRP3
53

OATP1B1
26

BCRP
71
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BCRP
713
 no
BSEP
377
 no
apomorphine glucuronide
3
CYP1A2
1532
 no
apomorphine glucuronide
3
CYP1A2
1532
 no
apomorphine glucuronide
3
CYP2B6
884
 no
CYP2B6
884
 no
apomorphine glucuronide
3
CYP2B6
884
 no
apomorphine glucuronide
3
CYP2C19
1392
 no
apomorphine glucuronide
3
CYP2C8
865
 no
apomorphine glucuronide
3
CYP2C9
1648
 no
apomorphine glucuronide
3
CYP2D6
1738
 no
apomorphine glucuronide
3
CYP3A4
1772
 no
CYP3A4
1772
 no
apomorphine glucuronide
3
CYP3A4/5
293
 no
apomorphine glucuronide
3
MATE2
251
 no
apomorphine glucuronide
3
MRP2
434
 no
MRP2
434
 no
apomorphine glucuronide
3
MRP3
200
 no
MRP4
226
 no
apomorphine glucuronide
3
OATP1B1
748
 no
OATP1B1
748
 no
apomorphine glucuronide
3
OATP1B3
666
 no
apomorphine glucuronide
3
OCT1
495
 no
OCT1
495
 no
apomorphine glucuronide
3
OCT2
595
 no
apomorphine glucuronide
3
P-gp
1514
 no
P-gp
1514
 no
apomorphine glucuronide
3
BCRP
713
 weak [Inhibition 50 uM]
apomorphine glucuronide
3
MATE1
292
 weak [Inhibition 50 uM]
apomorphine glucuronide
3
OAT1
558
 weak [Inhibition 50 uM]
apomorphine glucuronide
3
OAT3
590
 weak [Inhibition 50 uM]
apomorphine glucuronide
3
MRP3
200
 yes [IC50 50 uM]
apomorphine glucuronide
3
CYP1A2
1532
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2B6
616
 yes
CYP2C8
634
 yes
CYP3A4/5
76
 yes
UGT
173
 yes
sulfotransferases
33
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:48538
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:48538
ZINC
ZINC000000009073
http://zinc15.docking.org/substances/ZINC000000009073
eMolecules
901400
https://www.emolecules.com/cgi-bin/more?vid=901400
PubMed

PubMed

TitleDatePubMed
5-HT1A receptor agonists buspirone and gepirone attenuate apomorphine-induced aggressive behaviour in adult male Wistar rats.
2000 Dec
Dopamine agonists.
2001
A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.
2001
Compulsive checking behavior of quinpirole-sensitized rats as an animal model of Obsessive-Compulsive Disorder(OCD): form and control.
2001
Intrapallidal dopamine restores motor deficits induced by 6-hydroxydopamine in the rat.
2001
Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study.
2001
No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy).
2001
Acute trazodone and quipazine treatment attenuates apomorphine-induced aggressive behaviour in male rats without major impact on emotional behaviour or monoamine content post mortem.
2001 Apr
Inhibition of baclofen on morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity.
2001 Apr
The effects of apomorphine and haloperidol on memory consolidation in the day-old chick.
2001 Apr
Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation.
2001 Apr
Resolution of stroke deficits following contralateral grafts of conditionally immortal neuroepithelial stem cells.
2001 Apr
Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
2001 Apr
A nitric oxide-dopamine link pathway in organum vasculosum laminae terminalis of rat brain exerts control over blood pressure.
2001 Apr
Reduced dopaminergic activity in depressed suicides.
2001 Apr
Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo.
2001 Apr 1
Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage.
2001 Apr 13
Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration.
2001 Apr 15
Effects of dopamine and dopamine-active compounds on oxytocin and vasopressin production in rat neurohypophyseal tissue cultures.
2001 Apr 2
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism.
2001 Apr 27
Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice.
2001 Apr 27
NMDA glutamate receptor stimulation is required for the expression of D2 dopamine mediated responses in apomorphine primed 6-hydroxydopamine lesioned rats.
2001 Apr 6
Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats.
2001 Feb
Key issues from the clinical trials of apomorphine SL.
2001 Feb
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
2001 Feb
Microencapsulated bovine chromaffin cell xenografts into hemiparkinsonian rats: a drug-induced rotational behavior and histological changes analysis.
2001 Feb
Apomorphine in the treatment of Parkinson's disease.
2001 Feb
The role of neurochemical mechanisms of ventromedial hypothalamus in various models of anxiety in rats.
2001 Jan
The localization of dopamine D2 receptor mRNA in the human placenta and the anti-angiogenic effect of apomorphine in the chorioallantoic membrane.
2001 Jan 19
Erectile dysfunction.
2001 Jun
Startle and sensorimotor gating in rats lacking CCK-A receptors.
2001 Jun
Entopeduncular lesions facilitate and thalamic lesions depress spontaneous and drug-evoked motor behavior in the hemiparkinsonian rat.
2001 Jun 1
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
2001 Jun 15
Corticosterone selectively attenuates 8-OH-DPAT-mediated hypothermia in mice.
2001 Mar
Reproductive experience modulates dopamine-related behavioral responses.
2001 Mar
Increased sensitivity of dopamine systems following reproductive experience in rats.
2001 Mar
Stimulus properties of 7-OH-DPAT versus auto- and postsynaptic receptor-specific doses of quinpirole.
2001 Mar
Differential effects of 7-OH-DPAT on the development of behavioral sensitization to apomorphine and cocaine.
2001 Mar
Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence.
2001 Mar
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
2001 Mar
Neural modulation of visuomotor functions underlying prey-catching behaviour in anurans: perception, attention, motor performance, learning.
2001 Mar
Apomorphine-induced aggressive behaviour in para-chlorophenylalanine-treated male rats: implications to brain.
2001 Mar
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
2001 Mar
Potent, hydroxyl radical-scavenging effect of apomorphine with iron and dopamine perfusion in rat striatum.
2001 Mar 30
Oral drug therapy for erectile dysfunction.
2001 May
Pharmacology of erectile function and dysfunction.
2001 May
The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
2001 May
Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus.
2001 May
Interaction between D2 dopaminergic and glutamatergic excitatory influences on lower urinary tract function in normal and cerebral-infarcted rats.
2001 May
Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice.
2001 May
Patents

Patents

05939094
3
JP2009526755A
410
JP2011526596A
7
JP4800219B2
61
JPH083043A
3

Sample Use Guides

In Vivo Use Guide
The recommended starting dose of is 0.2 mL (2 mg). Titrate on the basis of effectiveness and tolerance, up to a maximum recommended dose of 0.6 mL (6 mg)
Route of Administration: Other
In Vitro Use Guide
Apomorphine at concentrations of higher than 2 x 10(-5) M dramatically reduced the growth-stimulatory effect of retinal pigment epithelium (RPE) cells on the scleral chondrocytes, whereas the inhibitory effect of apomorphine on the proliferation of scleral chondrocytes without RPE cells was very little
Substance Class Chemical
Created
by admin
on Sat Jun 26 01:32:11 UTC 2021
Edited
by admin
on Sat Jun 26 01:32:11 UTC 2021
Record UNII
N21FAR7B4S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
APOMORPHINE
HSDB   MI   VANDF   WHO-DD  
Common Name English
APOMORPHINUM
HPUS  
Common Name English
APOMORPHINE [HSDB]
Common Name English
APOMORPHINE [VANDF]
Common Name English
VR-040
Code English
APL-130277
Code English
VR040
Code English
4H-DIBENZO(DE,G)QUINOLINE-10,11-DIOL, 5,6,6A,7-TETRAHYDRO-6-METHYL-, (R)-
Common Name English
6A.BETA.-APORPHINE-10,11-DIOL
Common Name English
APOMORPHINUM [HPUS]
Common Name English
APOMORPHINE [WHO-DD]
Common Name English
APOMORPHINE [MI]
Common Name English
(6AR)-5,6,6A,7-TETRAHYDRO-6-METHYL-4H-DIBENZO(DE,G)QUINOLINE-10,11-DIOL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
WHO-ATC G04BE07
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
WHO-VATC QG04BE07
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
NDF-RT N0000175580
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
NCI_THESAURUS C38149
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
LIVERTOX 60
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
EU-Orphan Drug EU/3/01/072
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
FDA ORPHAN DRUG 89295
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
WHO-ATC N04BC07
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
NDF-RT N0000000117
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
FDA ORPHAN DRUG 107997
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
WHO-VATC QN04BC07
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
Code System Code Type Description
DRUG BANK
DB00714
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
MESH
D001058
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
PUBCHEM
6005
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
EPA CompTox
58-00-4
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
EVMPD
SUB12923MIG
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
ChEMBL
CHEMBL53
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
IUPHAR
33
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-360-0
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
CAS
58-00-4
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
MERCK INDEX
M2003
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C61639
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
FDA UNII
N21FAR7B4S
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
LACTMED
Apomorphine
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
HSDB
3289
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
DRUG CENTRAL
228
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
RXCUI
1043
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
APOMORPHINE
Created by admin on Sat Jun 26 01:32:11 UTC 2021 , Edited by admin on Sat Jun 26 01:32:11 UTC 2021
PRIMARY
Related Record Type Details
D(3) DOPAMINE RECEPTOR
TARGET -> AGONIST
Emax 82% Transfected CHO cells
EC50
D(4) DOPAMINE RECEPTOR
TARGET -> AGONIST
Emax 45% Emax 82% Transfected CHO cells
EC50
Structure of APOMORPHINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 1A2
METABOLIC ENZYME -> INDUCER
MAXIMUM FOLD INCREASE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of APOMORPHINE HYDROCHLORIDE ANHYDROUS
SALT/SOLVATE -> PARENT
POTASSIUM VOLTAGE-GATED CHANNEL SUBFAMILY H MEMBER 2
OFF-TARGET->INHIBITOR
BINDING
IC50
D(2) DOPAMINE RECEPTOR
TARGET -> AGONIST
D2S Primary receptor interaction.. Emax 79%
EC50
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
Structure of APOMORPHINE
EXCRETED UNCHANGED
INTRAVENOUS ADMINISTRATION
URINE
Related Record Type Details
Structure of APOMORPHINE PALMITATE
PRODRUG -> METABOLITE ACTIVE
Structure of APOMORPHINE DIACETATE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of APOMORPHINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC SUBCUTANEOUS ADMINISTRATION

CSF/PLASMA RATIO PHARMACOKINETIC Tmax
PHARMACOKINETIC
Route of Adminstration
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966